Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Identification of Pathogens Causing Bacterial Septicemia

By LabMedica International staff writers
Posted on 24 Aug 2010
A molecular based test is now available that will simultaneously identify three Gram-negative bacteria directly from positive blood cultures in less than 90 minutes.

A three-color multiplex assay allows for the identification of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from positive blood cultures.
Smears of blood cultures are heat fixed onto microscope slides, a drop of GNR Traffic Light peptide nucleic acid fluorescence in situ hybridization (PNA FISH) probe is added to the smear and then hybridized at 55 °C for 30 minutes. More...


The GNR Traffic Light PNA probe is mixture of a fluorescein-labeled E. coli-specific PNA probe, a fluorescein and tetramethylrhodamine labeled K. pneumoniae-specific
PNA probe and a Texas Red labeled P. aeruginosa-specific PNA probe.

The slides are then washed for 30 minutes at 55 °C. After which the slides are mounted and visualized with a fluorescence microscope with a FITC/Texas Red filter and 60× oil objective. E. coli is identified as green fluorescent cells, K. pneumoniae as yellow and P. aeruginosa as red. The GNR Traffic Light PNA FISH assay is the latest test from AdvanDx (Woburn MA, USA) and is now available in Europe. It is an addition to their easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results enabling clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections.

Studies show that providing a 24 hours "head start" on appropriate, narrow-spectrum therapy for Gram-negative bloodstream infections may improve clinical outcomes, reduce antibiotic resistance rates, and reduce the incidences of adverse events. GNR Traffic Light PNA FISH will enable microbiology labs to provide clinicians rapid, accurate Gram-negative pathogen identification results in hours, instead of days. Every year, close to 875,000 patients in the USA contract bloodstream infections, leading to over 150,000 deaths. The infection is detected when a culture of the patient's blood turns positive with bacteria or yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

Thais T. Johansen, M.B.A., president and CEO of AdvanDx, said, "The GNR Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections."

Related Links:
AdvanDx


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.